BENICIA, Calif.—Results published in the peer reviewed journal, International Journal of Medical Sciences, showed UC-II® significantly reduced pain, stiffness and immobility associated with osteoarthritis (2009;6:312-321). Researchers, in a randomized, double blind, 90-day study found 40 mg of InterHealth’s UC-II undenatured type II collagen was more than twice as effective as 1,500 mg of glucosamine + 1,200 mg of chondroitin. Decrease in joint pain, stiffness and immobility were measured by three reliable and accurate measurement indexes for osteoarthritis: WOMAC, VAS and Lequesne. UC-II significantly reduced WOMAC by 33 percent, VAS by 40 percent and Lequesne by 20 percent compared to 14 percent, 15 percent and 6 percent, respectively, with glucosamine + chondroitin.
“The clinical benefits we saw in osteoarthritic patients taking UC-II, showing significant overall improvement in conventional osteoarthritis efficacy measures, are positive clinical indicators that UC-II is highly effective at supporting joint health,” said corresponding study author Siba Raychaudhuri, M.D., rheumatologist at the Department of Medicine, Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California Davis and professor at VA Medical Center Sacramento, Mather, Calif. “While the overall benefits were impressive, it is important to note that reduction in pain and stiffness were seen as early as 30 days after taking UC-II.”
